Adenovirus T-cell therapy for hard-to-treat virus after transplants
Part of Genetic & congenital, Immune system & allergy, Infections clinical trials.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an adenovirus infection after a stem cell transplant or after a solid organ transplant
- Your adenovirus is not improving (or symptoms are ongoing) after at least 2 weeks of appropriate antiviral treatment
- You either have adenovirus-related symptoms (like lung, bladder bleeding, bowel inflammation, or liver inflammation) or a problem tolerating antivirals
- Your kidney function issue from a medicine like cidofovir was bad enough to be considered intolerable (about grade 2 renal insufficiency)
- You are able to participate based on your activity level (performance score over 30%) and can give informed consent
- You are not excluded by factors like severe graft-versus-host disease, needing stronger steroid doses, recent donor lymphocyte treatment, or ongoing participation in another adenovirus trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Hear when a new Adenovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.